T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Phase 1 Active not recruiting 9 enrolled Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

An open label, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301VT in subjects with advanced solid tumor.

Timeline

Start: 2025-12-15
Primary completion: 2027-02
Completion: 2032-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NW-301VT	Cell therapy	—	Intravenous

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Summary

Timeline

Drugs

Indications